Clinical trial
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV…
NCT00400803 · Masonic Cancer Center, University of Minnesota, Other · Completed
Key facts
| NCT number | NCT00400803 |
|---|---|
| Title | Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer |
| Official title | Phase II Study of Biweekly Carboplatin and Gemcitabine With Bevacizumab as 1st Line Treatment in Patients With Advanced, Inoperable Stage IIIb/IV NSCLC |
| Lead sponsor | Masonic Cancer Center, University of Minnesota, Other |
| Collaborators | Eli Lilly and Company Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | Gemcitabine, Carboplatin, Bevacizumab |
| Enrollment | 38 |
| Start date | Mar 1, 2007 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Nov 17, 2006 |
| Last update posted | Dec 28, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: